ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
This article is part of the Research TopicLatest Insights and Translational Advances in Obstructive Sleep Apnoea (OSA)View all 8 articles
Impact of Solriamfetol Treatment on Sleep Quality in Chinese Patients With OSA-EDS: Results of a Randomized Controlled Trial
Provisionally accepted
- 1Second Affiliated Hospital of Nanchang University, Nanchang, China
- 2Ignis Therapeutics Shanghai Limited, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Wake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA). However, the impact of solriamfetol on nocturnal sleep quality remains underexplored. This exploratory analysis of a 12-week, randomized, double-blind, placebo-controlled, multicenter, parallel-arm, phase 3 trial involving Chinese patients with OSA-EDS evaluated the effect of solriamfetol on nocturnal sleep quality. Methods: Participants were randomized (1:1) to receive solriamfetol (150 mg) or placebo once daily. The coprimary efficacy endpoints were the changes from baseline to Week 12 in mean sleep latency during the Maintenance Wakefulness Test and in Epworth Sleepiness Scale scores. The exploratory endpoints included changes in participants' polysomnography (PSG) parameters from baseline at Weeks 2, 5, and 12. These parameters were unadjusted and hypothesis-generating. The sleep quality parameters included total sleep time (TST) and wakefulness after sleep onset (WASO). Respiratory parameters included mean oxygen saturation (SaO2), minimum SaO2, apnea index, and apnea-hypopnea index (AHI). Results: Of the 357 participants screened, 201 were included in the full analysis set (FAS) (solriamfetol, n = 101; placebo, n = 100). At all time points (Weeks 2, 5, and 12), no significant changes in TST, WASO, stage N2 sleep, and AHI were observed between the solriamfetol and placebo groups (P > 0.05). No significant changes were observed in N1 and N3, although significant changes were observed in N1 at Week 2 (P = 0.0022) and N3 at Week 5 (P = 0.0212). Conclusion: No clinically significant or consistent changes in PSG parameters were observed compared with placebo, indicating that solriamfetol morning administration has no significant effect on nocturnal sleep parameters.
Keywords: excessive daytime sleepiness, obstructive sleep apnea, sleep parameter, sleep quality, solriamfetol, Total sleep time
Received: 24 Sep 2025; Accepted: 28 Jan 2026.
Copyright: © 2026 Wang, Deng, Xie, Jiang, Li, Zhang, Ye and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yongmin Ding
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.